ClinicalTrials.gg
CompletedNCT01916993Updated Jan 16, 2014

Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild,Moderate, or Severe Hepatic Insufficiency

A Phase 1 interventional study of NBI-98854 50 mg capsule in Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects, sponsored by Neurocrine Biosciences. Completed at 3 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-01-16.

Sponsored by Neurocrine Biosciences · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this research study is to: test the safety, tolerability, and pharmacokinetics (PK testing, the study of how the body absorbs, distributes, breaks down and eliminates a drug) of a single dose of the investigational study drug NBI-98854 in subjects with normal hepatic function or mild, moderate, or severe hepatic impairment.

02

Conditions studied

  • Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects
03

In context

Lead sponsor

Neurocrine Biosciences is the lead sponsor of 87 studies on the registry; 17 are open to participants now.

Of its 35 completed or terminated interventional studies of FDA-regulated products, 23 (66%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, 18 to 75 years of age.
  • Healthy volunteers must be in good general health.
  • Subjects with hepatic impairment must be judged to be in stable condition.
  • Subjects of must agree to use hormonal or two forms of nonhormonal during the study.
  • Female subjects must not be pregnant, given birth within 1 year of study start, or breastfeeding.
  • Have a (BMI) of 18 to 40 kg/m2 (both inclusive).

Exclusion criteria

Exclusion Criteria:

  • Report more than two alcoholic beverages daily or more than 14 alcoholic beverages weekly withing 7 days of study start.
  • Have a known history of neuroleptic malignant syndrome.
  • Have a positive (HIV) antibody result at screening or have a history of positive result.
  • Have received an drug within 30 days before screening or plan to use an investigational drug (other than NBI-98854) during the study.
  • Have an allergy, , or intolerance to tetrabenazine.
  • Had a blood loss greater than or equal to 500 mL or donated blood within 56 days of study start.
  • Have had previous exposure with NBI-98854.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Healthy Volunteers

    single dose of NBI-98854 50 mg capsule

    Drug: NBI-98854 50 mg capsule

  • Experimental
    Mild Hepatic Impairment

    single dose of NBI-98854 50 mg capsule

    Drug: NBI-98854 50 mg capsule

  • Experimental
    Moderate Hepatic Impairment

    single dose of NBI-98854 50 mg capsule

    Drug: NBI-98854 50 mg capsule

  • Experimental
    Severe Hepatic Impairment

    single dose of NBI-98854 50 mg capsule

    Drug: NBI-98854 50 mg capsule

Interventions

06

What researchers measure

Primary outcomes

  1. Evaluation of plasma concentrations of NBI-98854 and metabolites following administration of NBI-98854

    Time frame: 45 minutes prior to NBI-98854 dosing, and 15, 30, 45 minutes, and 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, and 120 hours postdose

  2. Number of Participants with Adverse Events following dosing with NBI-98854

    Time frame: Up to 36 days

07

Study locations

3 sites
  • DaVita Clinical Research
    Lakewood, Colorado 80228, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
  • Davita Clinical Research
    Minneapolis, Minnesota 55404, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2013, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2013
First posted
Aug 6, 2013
Start
Aug 2013
Primary completionActual
Dec 2013
CompletionActual
Dec 2013
Last update
Jan 16, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01916993
Responsible party
Sponsor
First posted
Aug 6, 2013
Start date
Aug 2013
Primary completion
Dec 2013
Completion
Dec 2013
Last update
Jan 16, 2014

Study contacts

Chris O'Brien, MD
study director · Neurocrine Biosciences

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valbenazine

Start the discussion